Common diabetes pill tested to stop blood cancer before it starts
NCT ID NCT04850846
Summary
This study is testing whether metformin, a common diabetes medication, can prevent people with early blood cell conditions (MGUS and smoldering myeloma) from developing full multiple myeloma, a type of blood cancer. About 60 participants will take either metformin or a placebo pill daily for 6 months to see if the drug slows disease progression. The goal is to find a safe, preventive treatment for people at risk of developing cancer who currently have no approved therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
DF/ BWCC in Clinical Affiliation with South Shore Hospital
Weymouth, Massachusetts, 02190, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber at Brighton
Brighton, Massachusetts, 02135, United States
-
Dana-Farber at Merrimack Valley
Methuen, Massachusetts, 01844, United States
-
Dana-Farber at Milford
Milford, Massachusetts, 01757, United States
-
Dana-Farber at NHOH
Londonderry, New Hampshire, 35053, United States
Conditions
Explore the condition pages connected to this study.